Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
175
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

208
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
208
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

282
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
282

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Methotrexate Cutaneous Delivery by Fractional CO2 Laser Against 5-Fluorouracil in Stable, Nonsegmental Vitiligo.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

Correction: Medication adherence and illness perception among diabetic patients in Upper Egypt.

BMC endocrine disorders·2026
Same author

Symptomatic stratification based on morphological features of carotid web (SCORE-WEB).

Frontiers in neurology·2026
Same author

Fibromuscular Dysplasia and Cerebrovascular Dissection: Insights From a Multicenter Cohort.

Journal of the American Heart Association·2026
Same author

Clinical Reasoning: A 56-Year-Old Woman With Right-Sided Weakness and Recurrent MRI Lesions.

Neurology·2025
Same author

Medication adherence and illness perception among diabetic patients in Upper Egypt.

BMC endocrine disorders·2025

相关实验视频

Updated: Jul 2, 2025

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

888

系统性甲胺是否在治疗梅拉斯玛中起作用?

Sahar A Ismail1, Ghada A Mohamed2, Karima N Mohamedeen3

  • 1Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
|February 28, 2024
PubMed
概括

系统性甲福明与三酸 (TCA) 剥离相结合,显著改善了美拉斯马. 甲胺为这种常见的色素状况提供了一种安全而有前途的新治疗方案,特别是对于皮肤色调较深的患者.

更多相关视频

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.2K

相关实验视频

Last Updated: Jul 2, 2025

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

888
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.2K

科学领域:

  • 皮肤病学 皮肤病学
  • 化品科学 化品科学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 黑色素是一种普遍的色素障碍,影响患者的生活质量.
  • 目前的黑色素瘤治疗方法往往不令人满意,特别是在肤色较暗的人群中.
  • 需要更有效,更安全的疹治疗方法.

研究的目的:

  • 评估口服甲福明与三酸 (TCA) 剥离结合治疗瘤的疗效和安全性.
  • 为了比较组合疗法与单独的TCA剥离.
  • 评估系统性甲福明的不同剂量 (1,000 mg和500 mg).

主要方法:

  • 一项涉及60名瘤患者的研究分为三个组.
  • 组A:每天1,000毫克口服甲福尔 + TCA 25%剥离.
  • B组:每天500毫克口服甲福尔 + TCA 25%剥离.
  • 组C:安慰剂+TCA25%剥离.
  • 治疗包括每两周进行一次面部TCA剥离,持续6次.
  • 使用梅拉斯马面积和严重性指数 (MASI) 和梅拉斯马生活质量量量表 (MELASQOL) 测量结果.

主要成果:

  • 所有治疗组都显示了治疗后MASI和MELASQOL得分的统计显著降低.
  • 与C组 (安慰剂+TCA) 相比,A组 (1,000毫克甲福尔+TCA) 的改善明显更好.
  • 这项研究表明,在治疗梅拉斯马时,对全身性甲福林的反应是积极的.

结论:

  • 系统性甲胺,与TCA剥离结合,为黑色素瘤提供了一种安全有效的治疗方法.
  • 甲胺显示承诺作为一种新的治疗选择,提供了改善的结果.
  • 这些发现表明,甲胺可以增强标准治疗的结果,如TCA剥离.